| Company Name: |
BOC Sciences Gold |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH manufacturers
- Pam3CSK41
-
- $398.00
-
2021-05-07
- CAS:112208-00-1
- Min. Order: 5mg
- Purity: 98%
- Supply Ability: 100mg
|
| | PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH Basic information |
| Product Name: | PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH | | Synonyms: | PAM3-CYS-SER-LYS-LYS-LYS-LYS-OH;PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH;PamCys-Ser-(Lys), Hydrochloride;n-palmitoyl-s-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-ly;sine;N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine;PaM3Cys-Ser-Lys-Lys-Lys-Lys-OH, PaM3CSK4;PaM3Cys-Ser-(Lys)4 . 3HCl | | CAS: | 112208-00-1 | | MF: | C81H156N10O13S | | MW: | 1510.23 | | EINECS: | | | Product Categories: | Pharmaceutical | | Mol File: | 112208-00-1.mol |  |
| | PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH Chemical Properties |
| Boiling point | 1408.0±65.0 °C(Predicted) | | density | 1.054±0.06 g/cm3(Predicted) | | storage temp. | -15°C | | solubility | Soluble to 1 mg/ml in 50% Ethanol / H2O | | form | Lyophilized solid | | pka | 3.27±0.10(Predicted) | | Water Solubility | water: 2mg/mL | | InChIKey | OEDPHAKKZGDBEV-GFPBKZJXSA-N |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| | PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH Usage And Synthesis |
| Uses | Pam3Cys-Ser-(Lys)4, Hydrochloride has been used to stimulate MODE-K cells to access its effects on epithelial neuropilin-1 (NRP1) protein expression. It has been used as a toll-like receptor 2 (TLR2) ligand to study TLR2 functionalities. | | General Description | A cell-permeable, water-soluble synthetic cationic lipohexapeptide analog of the immunologically active N-terminal portion of bacterial lipoprotein that potently activates monocytes and macrophages. Induces the release of IL-1, IL-6, TNF-α, superoxide, and NO. Promotes the translocation of NF-κB, enhances tyrosine protein phosphorylation and activation of ERK1/2 and MEK1/2. Acts as a selective agonist of TLR2 (Toll-like receptor 2).
A cell-permeable, water-soluble, synthetic, cationic lipohexapeptide analog of the immunologically active N-terminal portion of bacterial lipoprotein that potently activates monocytes and macrophages. Induces the release of IL-1, IL-6, TNF-α, superoxide and NO. Promotes the translocation of NF-κB, enhances tyrosine protein phosphorylation, and activates ERK1/2 and MEK1/2. Acts as a selective TLR-2 (Toll-like receptor 2) agonist. | | Biological Activity | pam3csk4 is an agonist of toll-like receptor 1/2 (tlr1/2) [1].toll-like receptors (tlrs) are proteins that play an important role in the innate immune system. tlrs are mainly expressed in sentinel cells that recognize molecules derived from microbes and then activate immune cell responses.pam3csk4 is a tlr1/2 agonist. pam3csk4 increased tyrosine phosphorylation of plcγ2 and the adaptor protein lat in a syk- and src-dependent way. also, pam3csk4 evoked platelet activation [1].in a mouse rhinitis model sensitized to dermatophagoides farinae allergen, pam3csk4 significantly improved the nasal allergic symptoms and reduced total inflammation cells and the eosinophils in bronchoalveolar lavage fluid (balf). also, pam3csk4 significantly increased ifn-γ release and decreased the levels of il-13 and total ige [2]. pam3csk4 induced the production of both no and tnf-ɑ by macrophages [3]. in a murine asthma model challenged with ova, pam3csk4 significantly reduced eosinophilia and total inflammatory cell infiltrate in balf and inhibited the secretion of il-4 and il-5 induced by ova. also, pam3csk4 reduced the level of ige and increased the production of il-12 [4]. | | in vivo | Pam3CSK4 (5 mg/kg; i.p.; once a day for 9 days) alters brain, spleen and liver weights in neonatal mice[3]. | Animal Model: | Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2tm1Kir/J (TLR2 -deficient) mice[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneally (i.p.); once a day for 9 days | | Result: | After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
| | IC 50 | TLR1; TLR2 | | storage | Store at -20°C |
| | PALMITOYL-CYS((RS)-2,3-DI(PALMITOYLOXY)-PROPYL)-SER-LYS-LYS-LYS-LYS-OH Preparation Products And Raw materials |
|